Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

146
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
146
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
134
Dialysis01:27

Dialysis

228
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
228
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

744
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
744
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.

Kidney international reports·2026
Same author

Percutaneous Image-Guided Non-Target Renal Biopsy in Cancer Patients: A Tertiary Cancer Center Experience.

Current oncology (Toronto, Ont.)·2026
Same author

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

Journal of the American Society of Nephrology : JASN·2026
Same author

Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy.

Kidney medicine·2026
Same author

Who is leading medical AI? A systematic review and scientometric analysis of chest x-ray research.

medRxiv : the preprint server for health sciences·2026
Same author

Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review.

Expert opinion on drug safety·2026

Related Experiment Video

Updated: May 10, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

5.6K

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury.

Shruti Gupta1,2,3, Ilya G Glezerman4, Jamie S Hirsch5,6,7

  • 1Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

JAMA Oncology
|April 24, 2025
PubMed
Summary

Prophylactic intravenous magnesium may reduce the risk of cisplatin-associated acute kidney injury (CP-AKI) in cancer patients. This study found a lower incidence of CP-AKI or death in patients receiving IV magnesium alongside cisplatin chemotherapy.

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.7K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.0K

Related Experiment Videos

Last Updated: May 10, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

5.6K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.7K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.0K

Area of Science:

  • Nephrology
  • Oncology
  • Pharmacology

Background:

  • Cisplatin-associated acute kidney injury (CP-AKI) is a significant complication of cisplatin chemotherapy, leading to increased morbidity and mortality.
  • Animal studies suggest prophylactic intravenous (IV) magnesium can mitigate CP-AKI, but human data are limited.

Purpose of the Study:

  • To assess the association between prophylactic IV magnesium administration and CP-AKI in cancer patients receiving cisplatin chemotherapy.
  • To evaluate the impact of IV magnesium on CP-AKI or death within 14 days of cisplatin treatment.

Main Methods:

  • A multicenter cohort study included 13,719 adult cancer patients treated with IV cisplatin between 2006-2022.
  • Patients receiving IV magnesium on the first day of cisplatin treatment were compared to those who did not, using inverse probability treatment weighting.
  • CP-AKI was defined as a 2-fold increase in serum creatinine or receipt of kidney replacement therapy within 14 days.

Main Results:

  • 28.4% of patients received prophylactic IV magnesium.
  • The incidence of CP-AKI or death was lower in the IV magnesium group (2.7%) compared to the no-IV magnesium group (5.3%).
  • The adjusted odds ratio for CP-AKI or death with IV magnesium was 0.80 (95% CI, 0.66-0.97), with consistent findings in sensitivity analyses.

Conclusions:

  • Prophylactic IV magnesium administration was associated with a reduced risk of CP-AKI in cancer patients undergoing cisplatin chemotherapy.
  • These findings suggest a potential protective role for IV magnesium against cisplatin-induced nephrotoxicity.
  • Randomized clinical trials are warranted to confirm these results and establish definitive clinical recommendations.